Evidence map›Paper›PMID 36768280›Full record

ArticleInternational journal of molecular sciences2023

In Silico and In Vitro Inhibition of SARS-CoV-2 PL

Sara Protić, Nevena Kaličanin, Milan Sencanski, Olivera Prodanović, Jelena Milicevic, Vladimir Perovic, Slobodan Paessler, Radivoje Prodanović, Sanja Glisic

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Molecular Interactions and Mechanisms of COVID-19 Inhibition 2.0.International journal of molecular sciences · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sara ProtićUniversity of Belgrade-Faculty of Chemistry, Studentski trg 12, 11000 Belgrade, Serbia.
Nevena KaličaninUniversity of Belgrade-Institute of Chemistry, Technology and Metallurgy, Njegoševa 12, 11000 Belgrade, Serbia.
Milan SencanskiLaboratory of Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences Vinca, National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.ORCID 0000-0002-7296-3223
Olivera ProdanovićUniversity of Belgrade-Institute for Multidisciplinary Studies, Kneza Višeslava 1, 11030 Belgrade, Serbia.
Jelena MilicevicLaboratory of Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences Vinca, National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.
Vladimir PerovicLaboratory of Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences Vinca, National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.ORCID 0000-0002-3700-6452
Slobodan PaesslerDepartment of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Radivoje ProdanovićUniversity of Belgrade-Faculty of Chemistry, Studentski trg 12, 11000 Belgrade, Serbia.ORCID 0000-0003-4662-1825
Sanja GlisicLaboratory of Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences Vinca, National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.

Funding

Science Fund of the Republic of Serbia 7551100 - COVIDTARGET - Repurposing of drugs for prevention and treatment of COVID-19
6 · The paper itself

Abstract

Finding an effective drug to prevent or treat COVID-19 is of utmost importance in tcurrent pandemic. Since developing a new treatment takes a significant amount of time, drug repurposing can be an effective option for achieving a rapid response. This study used a combined in silico virtual screening protocol for candidate SARS-CoV-2 PL

Indexed as

COVID-19SARS-CoV-2Antiviral AgentsDatabases, FactualGramicidinHumansMolecular Docking SimulationProtease InhibitorsAntiviral AgentsGramicidinProtease Inhibitorsanti SARS-CoV-2COVID-19gramicidin DPLproPLpro candidate inhibitor

Identifiers

PMID36768280
PMCPMC9915632

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.